PATIENT ALERT: Information regarding Coronavirus (COVID-19). CLICK HERE for more information about our office relocations. 

Clinical Research & Trials

Available Trials

Throughout the last century, the medical community has witnessed dramatic changes in the methods of diagnosis and treatment of cancer. Cancer research is no longer conducted exclusively at large university cancer centers or major metropolitan hospitals. Virginia Oncology Associates' physicians have embraced clinical cancer research as a critical component of community-based oncology care. Through a partnership with Duke University Oncology Consortium, National Cancer Institute, and US Oncology, VOA physicians are able to provide cancer patients with innovative treatment options and therapies. Virginia Oncology Associates offers the largest clinical research program in all of Hampton Roads. You do not have to leave the area to receive premier cancer care.

If you are interested in learning more about our research program, please call the VOA Research Department in the area closest to you:

Peninsula: (757) 873-9400

  • Hampton
  • Newport News
  • Williamsburg

Southside: (757) 466-8683

  • Norfolk
  • Virginia Beach


Breast Cancer Research

  • USO 20164

    A Phase II, Multicenter, Open Label Study Of Bintrafusp Alfa (M7824) Monotherapy In Participants With HMGA2-Expressing Triple Negative Breast Cancer (MS200647_0020)

    Available at 5 locations

    View Details

  • USO 19226

    A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (BO41843)

    Available at 3 locations

    View Details

  • USO 19122

    A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Assess The Efficacy And Safety Of Alpelisib (BYL719) In Combination With Nab-Paclitaxel In Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-Kinase Catalytic Subunit Alpha (PIK3CA) Mutation Or Phosphatase And Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation (CBYL719H12301)

    Available at 2 locations

    View Details

  • MERCK KEYLYNK MK7339-009

    An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit with First-line Chemotherapy Plus Pembrolizumab in Participants with Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC)(KEYLYNK-009)

    Available at 3 locations

    View Details

  • USO 19009

    A Multicenter, Phase 2 Study of Tesetaxel plus Three Different PD-(L)1 Inhibitors in Patients with Triple-Negative, Locally Advanced or Metastatic Breast Cancer and Tesetaxel Monotherapy in Elderly Patients with HER2 Negative, Locally Advanced or Metastatic Breast Cancer (ODO-TE-B202)

    Available at 3 locations

    View Details

  • USO 17188

    A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

    Available at 5 locations

    View Details

GYN Cancer Research

  • USO 20225

    A Phase 2, Multicenter, Single-Arm, Open-Label Study To Evaluate The Efficacy And Safety Of AK104 In Subjects With Recurrent Or Metastatic Cervical Cancer (AK104-201-AU) STAR

    Available at 3 locations

    View Details

  • USO 19221

    A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Pa;clitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E) (D9311C00001;GOG-3041; ENGOT-EN10)

    Available at 2 locations

    View Details

  • USO 18269

    Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant with Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer ( ENGOT-ov50 / INNOVATE-3)

    Available at 1 location

    View Details

  • USO 17182

    Clovis A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ClovisCO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA)

    Available at 3 locations

    View Details

Gastrointestinal Cancer Research

  • USO 20235

    A Phase 3 Randomized, Double-blind Trial of Trilaciclib versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer: PRESERVE 1 (G1T28-207)

    Available at 5 locations

    View Details

  • USO 20286

    Screening Protocol To Detect HER2 Alterations Required For Enrollment On Clinical Research Protocols Of Tucatinib (SGN00-002)

    Available at 5 locations

    View Details

  • USO 19245

    USO 19245: A Global, Multicenter, Randomized, Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer (FRESCO-2) (2019-013-GLOB1)

    Available at 4 locations

    View Details

Genitourinary Cancer Research

  • USO 19236

    A Phase III, Multicenter, Randomized, Open-Label Study To Evaluate The Efficacy And Safety Of Atezolizumab Given In Combination With Cabozantinib Versus Cabozantinib Alone In Patients With Inoperable, Locally Advanced, Or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During Or After Immune Checkpoint Inhibitor Treatment (WO41994)

    Available at 3 locations

    View Details

  • USO 19144

    Biomarker Study To Determine Frequency Of DNA-Repair Defects In Men With Metastatic Prostate Cancer (64091742PCR0002)

    Available at 5 locations

    View Details

  • USO 18033

    A Phase 2 Study Of Sitravatinib In Combination With PD-(L)1 Checkpoint Inhibitor Regimens On Patients With Advanced Or Metastatic Urothelial Carcinoma (516-003)

    Available at 5 locations

    View Details

  • PSMA 302

    PSMA 302: A Prospective, Phase 3, Multi-Center, Single-Arm, Imaging Study Investigating The Safety And Diagnostic Performance Of Rhpsma-7.3 (18F) PET Ligand In Men With Suspected Prostate Cancer Recurrence Based On Elevated PSA Following Prior Therapy.

    Available at 3 locations

    View Details

  • PSMA 301

    PSMA 301: A prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating The Safety And Diagnostic Performance Of rhPSMA 7.3 (18F) PET Ligand In Men With Newly Diagnosed Prostate Cancer

    Available at 3 locations

    View Details

  • USO 19094

    Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302) (QBGJ398-302)

    Available at 1 location

    View Details

  • USO 17133

    A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR) (42756493BLC3001)

    Available at 1 location

    View Details

  • USO 19032

    Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

    Available at 2 locations

    View Details

  • USO 18283

    A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy (IMMU-132-06)

    Available at 3 locations

    View Details

  • USO 18095

    A Phase 3, Randomized, Open-Label Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer (CA017078)

    Available at 5 locations

    View Details

  • JANSSEN 56021927PCR2032

    JANSSEN 56021927PCR2032: An Open-label, Multicenter, Phase Ib Study of JNJ-63723283, a PD-1 Inhibitor, Administered in Combination with Apalutamide in Subjects with Metastatic Castration-Resistant Prostate Cancer

    Available at 1 location

    View Details

  • USO 17165

    Phase 1b/2 Study to Evaluate Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Erdafitinib Plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects With Metastatic or Surgically Unresectable Urothelial Cancer With Selected FGFR Gene Alterations (42756493BLC2002)

    Available at 1 location

    View Details

Hematology

  • USO 20219

    A Dual-Cohort, Open-Label, Phase 2 Study Of Brentuximab Vedotin And CHP (A+CHP) In The Frontline Treatment Of Subjects With Peripheral T-Cell Lymphoma (PTCL) With Less Than 10% CD30 Expression (SGN35-032)

    Available at 5 locations

    View Details

  • USO 18177

    A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) (ASTX727-03)

    Available at 1 location

    View Details

Leukemia & Lymphoma Research

  • USO 18281

    A Phase 1a/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with CLL/SLL or Non-Hodgkin's Lymphomas (APTO-CG-806-01)

    Available at 1 location

    View Details

  • USO 18104

    A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (017007)

    Available at 1 location

    View Details

Lung Cancer Research

  • USO 20381

    Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)

    Available at 5 locations

    View Details

  • USO 20283

    A Phase 2 Study Of Brentuximab Vedotin In Combination With Pembrolizumab In Subjects With Metastatic Solid Malignancies After Progression On Prior PD-1 Inhibitor Treatment (SGN35-033)

    Available at 5 locations

    View Details

  • USO 20137

    A Phase III, Open-Label, Randomized Study Of Atezolizumab And Tiragolumab Compared With Durvalumab In Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation (GO41854)

    Available at 5 locations

    View Details

  • USO 19143

    A Phase 3 Multicenter, Randomized, Open Label, Active-Controlled, Study Of AMG 510 Versus Docetaxel For The Treatment Of Previously Treated Locally Advanced And Unresectable Or Metastatic NSCLC Subjects With Mutated KRAS P.G12C (20190009)

    Available at 5 locations

    View Details

  • USO 19209

    A Non-interventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in Subjects with Non-Small Cell Lung Cancer (NSCLC) (20190294)

    Available at 5 locations

    View Details

  • USO 19109

    A Phase I Dose Escalation And Expanded Cohort Study Of Pf-06821497 In The Treatment Of Adult Patients With Relapsed/Refractory Small Cell Lung Cancer (Sclc), Castration Resistant Prostate Cancer (Crpc) And Follicular Lymphoma (Fl) (C2321001)

    Available at 1 location

    View Details

  • USO 18234

    A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer (AB928CSP0004)

    Available at 1 location

    View Details

Multiple Myeloma

  • USO 19247

    A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)

    Available at 5 locations

    View Details

Solid Tumors Research

  • USO 19151

    A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) STAR

    Available at 1 location

    View Details

  • USO 19079

    A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) (INCB 54828-207)

    Available at 2 locations

    View Details

  • LOXO-EXT-17005

    LOXO-EXT-17005: Phase 1/2 Study Of The TRK Inhibitor LOXO-195 In Adult And Pediatric Subjects With Previously Treated NTRK Fusion Cancers

    Available at 1 location

    View Details

  • USO 18057

    A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors (CA030-001)

    Available at 1 location

    View Details

  • Ignyta (RXDX 101-02)

    An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

    Available at 1 location

    View Details